Investment: “Allogenetics raises €3.8M”
Allogenetics, a Hanover, Germany-based biotechnology company developing a one-time ex vivo gene therapy approach to improve organ transplantation outcomes, raised €3.8M in a Pre-Series A round led by NBank Capital.
The round included participation from CARMA FUND, Life Science Valley Wachstumsfonds and additional corporate and private investors.
Led by CEO Oliver Ernst, PhD, Allogenetics is advancing an ex vivo gene therapy designed as a one-time treatment to modify donor organs with the goal of reducing and potentially eliminating the need for lifelong immunosuppression. Its platform enables a calibrated knockdown of cell-surface antigen presentation (MHC class I and II) to evade graft rejection while retaining full immune competence, providing an organ-agnostic approach that begins with lung grafts.
The company intends to use the proceeds to support its lead program, ALG-115, through IND-enabling studies toward clinical evaluation in lung transplantation.
